This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Nektar (NKTR) Q3 Earnings & Sales Surpass, Sales View Up
by Zacks Equity Research
Nektar's (NKTR) earnings and revenues beat estimates in Q3. The company also raises its revenue guidance for the same period.
Infinity (INFI) Q3 Loss Narrower than Expected, View Intact
by Zacks Equity Research
Infinity Pharmaceuticals (INFI) Q3 loss was narrower than estimates and the year-ago quarter loss.
Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q3 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday.
AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda
by Zacks Equity Research
AVEO Pharmaceuticals reported narrower-than-expected adjusted loss in the third quarter. Moreover, it received approval for its first drug, Fotivda, which was approved in EU for bladder cancer.
Horizon Pharma (HZNP) Tops Q3 Earnings & Sales, Ups View
by Zacks Equity Research
Horizon Pharma (HZNP) Q3 results were driven by growth from the orphan and rheumatology business.
Pharma Stock Roundup: Pfizer, Teva's Q3 Earnings, Novartis Seeks New Indication for Kymriah
by Arpita Dutt
It was all about earnings last week with companies like Pfizer (PFE), Teva and Allergan reporting third quarter results.
The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical
Zacks.com highlights: Bristol-Myers Squibb, Quintiles IMS Holdings, Intel, CoreSite Realty and Curtiss-Wright
by Zacks Equity Research
Zacks.com highlights: Bristol-Myers Squibb, Quintiles IMS Holdings, Intel, CoreSite Realty and Curtiss-Wright
Zacks.com highlights: Bristol-Myers Squibb, Quintiles IMS Holdings, Intel, CoreSite Realty and Curtiss-Wright
by Zacks Equity Research
Zacks.com highlights: Bristol-Myers Squibb, Quintiles IMS Holdings, Intel, CoreSite Realty and Curtiss-Wright
Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Clovis (CLVS) witnessed narrower year-over-year loss in the third quarter. Also, the company's revenues missed estimates. Rubraca adoption slower.
Exelixis (EXEL) Beats Q3 Earnings on Solid Cabometyx Sales
by Zacks Equity Research
Exelixis (EXEL) beat both earnings and sales estimates in the third quarter fueled by strong demand for Cabometyx for RCC.
Upgraded Broker Ratings Make These 5 Stocks Worth Investing
by Zacks Equity Research
Broker advice helps to choose the right stocks as they have deeper insight into fundamentals.
5 Biotech and Pharma Stocks with Key FDA Catalysts this November
by Arpita Dutt
Here is a look at five biotech and pharma stocks including Dynavax (DVAX) that have an important regulatory event lined up this month.
The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, Bristol-Myers, Weyerhaeuser and Colgate
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, Bristol-Myers, Weyerhaeuser and Colgate
Aduro (ADRO) Q3 Loss In Line With Estimates, Revenues Miss
by Zacks Equity Research
Aduro BioTech's (ADRO) third-quarter results were unimpressive with the company reporting loss as expected and revenues missing estimates.
Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.
Is AVEO Pharmaceuticals Poised for a Beat in Q3 Earnings?
by Zacks Equity Research
AVEO Pharmaceuticals received approval for its first drug, Fotivda, as first-line treatment for RCC in Europe during the quarter. This is likely to have a favorable impact on third-quarter results.
What's in the Cards for PFE, INCY and ACOR in Q3 Earnings?
by Zacks Equity Research
The third-quarter reporting cycle is witnessing accelerating revenues and positive revisions trend for Q4. Let's see if some of the other leading players like Pfizer, Incyte and Acorda follow suit.
What's in the Offing for Exelixis (EXEL) in Q3 Earnings?
by Zacks Equity Research
Exelixis, Inc. (EXEL) received a major boost with the FDA's approval of Cabometyx tablets and we expect investor focus on the drug's uptake when it reports third-quarter results.
Seattle Genetics (SGEN) Loss Narrows in Q3, Revenues Beat
by Zacks Equity Research
Seattle Genetics (SGEN) reported narrower-than-estimated loss in the third quarter. Moreover, including a warrant exercise it turned profitable. The shares were up in response.
Company News For Oct 27, 2017
by Zacks Equity Research
Companies in the news are: TWTR,F,BMY,ABMD
Gilead (GILD) Down on Weak HCV Sales Despite Q3 Earnings Beat
by Zacks Equity Research
Although Gilead Sciences (GILD) topped estimates in the third quarter, weak HCV sales has dampened investors sentiment.
Pharma Stock Roundup: Lilly Tops on All Fronts, Mixed Results from Bristol-Myers
by Arpita Dutt
It was all about earnings this week with companies like Eli Lilly (LLY), Bristol-Myers Squibb and Novartis reporting third quarter results.
Bristol-Myers (BMY) Misses on Q3 Earnings, Opdivo in Focus
by Zacks Equity Research
Bristol-Myers (BMY) Q3 earnings miss estimates while revenues beat the same. Opdivo's label was expanded to two more indications.
Bristol-Myers (BMY) Q3 Earnings Miss Estimates
by Zacks Equity Research
Bristol-Myers (BMY) miss estimates, however, revenues were above expectations.